These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6801103)

  • 41. Glycosidases in skin and plasma in Hunter's syndrome. Abnormality of a beta-galactosidase in skin.
    Ockerman PA; Köhlin P
    Acta Paediatr Scand; 1968 Jul; 57(4):281-4. PubMed ID: 4236601
    [No Abstract]   [Full Text] [Related]  

  • 42. Mucopolysaccharidosis II (Hunter's syndrome).
    Arch Dermatol; 1970 Nov; 102(5):578-80. PubMed ID: 4248769
    [No Abstract]   [Full Text] [Related]  

  • 43. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome).
    Martin R; Beck M; Eng C; Giugliani R; Harmatz P; Muñoz V; Muenzer J
    Pediatrics; 2008 Feb; 121(2):e377-86. PubMed ID: 18245410
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mild and severe Hunter syndrome (MPS II) within the same sibships.
    Yatziv S; Erickson RP; Epstein CJ
    Clin Genet; 1977 May; 11(5):319-26. PubMed ID: 140775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hunter's disease in a girl: association with X:5 chromosomal translocation disrupting the Hunter gene.
    Mossman J; Blunt S; Stephens R; Jones EE; Pembrey M
    Arch Dis Child; 1983 Nov; 58(11):911-5. PubMed ID: 6418082
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical response to long term enzyme replacement treatment in children, adolescent and adult patients with Hunter syndrome.
    Dalmau Serra J; Vitoria Miñana I; Calderón Fernández R; Cortell Aznar I
    Med Clin (Barc); 2015 Nov; 145(9):392-8. PubMed ID: 26360015
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prenatal diagnosis and genetic counseling of mucopolysaccharidosis type II (Hunter syndrome).
    Chen CP; Lin SP; Tzen CY; Hwu WL; Chern SR; Chuang CK; Chiang SS; Wang W
    Genet Couns; 2007; 18(1):49-56. PubMed ID: 17515300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).
    Muenzer J; Gucsavas-Calikoglu M; McCandless SE; Schuetz TJ; Kimura A
    Mol Genet Metab; 2007 Mar; 90(3):329-37. PubMed ID: 17185020
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase.
    Bach G; Eisenberg F; Cantz M; Neufeld EF
    Proc Natl Acad Sci U S A; 1973 Jul; 70(7):2134-8. PubMed ID: 4269173
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The mucopolysaccharidoses types I, II, and 3: urinary findings in 23 cases.
    Gordon BA; Haust MD
    Clin Biochem; 1970 Sep; 3(3):203-15. PubMed ID: 4258598
    [No Abstract]   [Full Text] [Related]  

  • 52. A method for the quantitative determination of urinary glycosaminoglycans.
    Hurst RE; Settine JM; Lorincz AE
    Clin Chim Acta; 1976 Aug; 70(3):427-32. PubMed ID: 133005
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).
    Okuyama T; Tanaka A; Suzuki Y; Ida H; Tanaka T; Cox GF; Eto Y; Orii T
    Mol Genet Metab; 2010 Jan; 99(1):18-25. PubMed ID: 19773189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Biochemical analysis of the intercellular matrix during development of chick embryo skin. II. The glycosaminoglycan component].
    Pane G; Wegelin I
    Boll Soc Ital Biol Sper; 1975 Aug; 51(15-16):968-72. PubMed ID: 130149
    [No Abstract]   [Full Text] [Related]  

  • 55. Glycosaminoglycans can be associated with oxidative damage in mucopolysaccharidosis II patients submitted to enzyme replacement therapy.
    Negretto GW; Deon M; Biancini GB; Burin MG; Giugliani R; Vargas CR
    Cell Biol Toxicol; 2014 Aug; 30(4):189-93. PubMed ID: 25022704
    [No Abstract]   [Full Text] [Related]  

  • 56. Thin-layer gel filtration of urinary acid mucopolysaccharides in Hunter's syndrome and in normal individuals.
    Taniguchi N
    Clin Chim Acta; 1970 Dec; 30(3):801-8. PubMed ID: 4250207
    [No Abstract]   [Full Text] [Related]  

  • 57. Reliability of the Booth-Nadler technique for the detection of Hunter heterozygotes.
    Donnelly PV; Di Ferrante N
    Pediatrics; 1975 Sep; 56(3):429-33. PubMed ID: 808791
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Demonstration of the heterozygous state in Hunter's syndrome.
    Booth CW; Nadler HL
    Pediatrics; 1974 Mar; 53(3):396-9. PubMed ID: 4273646
    [No Abstract]   [Full Text] [Related]  

  • 59. The origin of glycosaminoglycans in baboon urine during the menstrual cycle.
    Naidoo SS; Qureshi AM
    Can J Physiol Pharmacol; 1974 Apr; 52(2):206-14. PubMed ID: 4275602
    [No Abstract]   [Full Text] [Related]  

  • 60. Glycosaminoglycans and glycosaminoglycan-degrading enzyme of Rana catesbeiana back skin during late stages of metamorphosis.
    Lipson MJ; Cerskus RA; Silbert JE
    Dev Biol; 1971 Jun; 25(2):198-208. PubMed ID: 4254586
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.